Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK.
Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Lancet Glob Health. 2021 Jan;9(1):e33-e43. doi: 10.1016/S2214-109X(20)30393-4. Epub 2020 Nov 26.
Human metapneumovirus is a common virus associated with acute lower respiratory infections (ALRIs) in children. No global burden estimates are available for ALRIs associated with human metapneumovirus in children, and no licensed vaccines or drugs exist for human metapneumovirus infections. We aimed to estimate the age-stratified human metapneumovirus-associated ALRI global incidence, hospital admissions, and mortality burden in children younger than 5 years.
We estimated the global burden of human metapneumovirus-associated ALRIs in children younger than 5 years from a systematic review of 119 studies published between Jan 1, 2001, and Dec 31, 2019, and a further 40 high quality unpublished studies. We assessed risk of bias using a modified Newcastle-Ottawa Scale. We estimated incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFRs) of human metapneumovirus-associated ALRI using a generalised linear mixed model. We applied incidence and hospital admission rates of human metapneumovirus-associated ALRI to population estimates to yield the morbidity burden estimates by age bands and World Bank income levels. We also estimated human metapneumovirus-associated ALRI in-hospital deaths and overall human metapneumovirus-associated ALRI deaths (both in-hospital and non-hospital deaths). Additionally, we estimated human metapneumovirus-attributable ALRI cases, hospital admissions, and deaths by combining human metapneumovirus-associated burden estimates and attributable fractions of human metapneumovirus in laboratory-confirmed human metapneumovirus cases and deaths.
In 2018, among children younger than 5 years globally, there were an estimated 14·2 million human metapneumovirus-associated ALRI cases (uncertainty range [UR] 10·2 million to 20·1 million), 643 000 human metapneumovirus-associated hospital admissions (UR 425 000 to 977 000), 7700 human metapneumovirus-associated in-hospital deaths (2600 to 48 800), and 16 100 overall (hospital and community) human metapneumovirus-associated ALRI deaths (5700 to 88 000). An estimated 11·1 million ALRI cases (UR 8·0 million to 15·7 million), 502 000 ALRI hospital admissions (UR 332 000 to 762 000), and 11 300 ALRI deaths (4000 to 61 600) could be causally attributed to human metapneumovirus in 2018. Around 58% of the hospital admissions were in infants under 12 months, and 64% of in-hospital deaths occurred in infants younger than 6 months, of which 79% occurred in low-income and lower-middle-income countries.
Infants younger than 1 year have disproportionately high risks of severe human metapneumovirus infections across all World Bank income regions and all child mortality settings, similar to respiratory syncytial virus and influenza virus. Infants younger than 6 months in low-income and lower-middle-income countries are at greater risk of death from human metapneumovirus-associated ALRI than older children and those in upper-middle-income and high-income countries. Our mortality estimates demonstrate the importance of intervention strategies for infants across all settings, and warrant continued efforts to improve the outcome of human metapneumovirus-associated ALRI among young infants in low-income and lower-middle-income countries.
Bill & Melinda Gates Foundation.
人类偏肺病毒是一种常见的病毒,与儿童急性下呼吸道感染(ALRI)有关。目前尚无全球儿童人类偏肺病毒相关 ALRI 负担的估计值,也没有针对人类偏肺病毒感染的许可疫苗或药物。本研究旨在估计全球 5 岁以下儿童中与人类偏肺病毒相关的 ALRI 的年龄分层发病率、住院率和死亡率。
我们从 2001 年 1 月 1 日至 2019 年 12 月 31 日期间发表的 119 项研究和另外 40 项高质量未发表的研究中对 5 岁以下儿童中与人类偏肺病毒相关的 ALRI 进行了系统评价,以估计全球负担。我们使用改良的纽卡斯尔-渥太华量表评估了偏倚风险。我们使用广义线性混合模型估计了人类偏肺病毒相关 ALRI 的发病率、住院率和住院病死率(hCFR)。我们将人类偏肺病毒相关 ALRI 的发病率和住院率应用于人口估计,以按年龄组和世界银行收入水平计算发病率负担估计值。我们还估计了 5 岁以下儿童中与人类偏肺病毒相关的住院死亡人数和总死亡率(包括住院和非住院死亡)。此外,我们通过将人类偏肺病毒相关负担估计值与实验室确诊的人类偏肺病毒病例和死亡中的归因分数相结合,估计了人类偏肺病毒相关的 ALRI 病例、住院和死亡。
2018 年,全球 5 岁以下儿童中,估计有 1420 万例人类偏肺病毒相关的 ALRI 病例(不确定区间[UR]为 1020 万至 2010 万),64.3 万例人类偏肺病毒相关的住院病例(UR 为 42.5 万至 97.7 万),7700 例人类偏肺病毒相关的院内死亡病例(2600 至 48800 例),以及 16100 例(医院和社区)与人类偏肺病毒相关的 ALRI 死亡病例(5700 至 88000 例)。2018 年,估计有 1110 万例 ALRI 病例(UR 为 800 万至 1570 万)、50.2 万例 ALRI 住院病例(UR 为 33.2 万至 76.2 万)和 11300 例 ALRI 死亡病例(4000 至 61600 例)可能与人类偏肺病毒有关。约 58%的住院病例发生在 12 个月以下的婴儿,64%的住院死亡发生在 6 个月以下的婴儿,其中 79%发生在低收入和中下收入国家。
在所有世界银行收入地区和所有儿童死亡率环境中,1 岁以下婴儿感染人类偏肺病毒的严重风险都不成比例地高,这与呼吸道合胞病毒和流感病毒相似。在低收入和中下收入国家,6 个月以下的婴儿死于人类偏肺病毒相关 ALRI 的风险高于年龄较大的儿童和中高收入和高收入国家的婴儿。我们的死亡率估计表明,在所有环境中,针对婴儿的干预策略都很重要,并证明有必要继续努力改善低收入和中下收入国家中婴儿人类偏肺病毒相关 ALRI 的结局。
比尔及梅琳达·盖茨基金会。